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SUMMARY 
 
Tumour Necrosis Factor (TNF) can drive inflammation, cell survival and death. While 
ubiquitylation-, phosphorylation- and NF-kB-dependent checkpoints suppress the 
cytotoxic potential of TNF, it remains unclear whether ubiquitylation can directly 
repress TNF-induced death. Here we show that cIAP1 regulates RIPK1 kinase activity 
not only via activation of downstream kinases and NF-kB transcriptional responses, 
but also by directly repressing RIPK1 kinase activity via Ubiquitin-dependent 
inactivation. We find that the UBiquitin-Associated (UBA) domain of cIAP1 is required 
for optimal Ubiquitin~Lysine occupancy and K48-ubiquitylation of RIPK1. Independent 
of IKK and MK2, UBA-mediated ubiquitylation suppresses RIPK1 kinase auto-
activation and, in addition, marks it for proteasomal degradation. In the absence of a 
functional UBA domain of cIAP1, more active RIPK1 kinase accumulates in response 
to TNF, causing RIPK1 kinase-mediated cell death and systemic inflammatory 
response syndrome. These results reveal a direct role for cIAP-mediated ubiquitylation 
in controlling RIPK1 kinase activity and preventing TNF-mediated cytotoxicity. 
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Introduction 
Inflammation and cell death are ancient processes of fundamental biological importance that 
enable survival and adaptation during infection and injury. Tumour necrosis factor (TNF) is a 
potent inflammatory cytokine that signals, through its type 1 receptor (TNF-R1), either cell 
survival, cell proliferation or cell death (Quistad and Traylor-Knowles, 2016; Walczak, 2011). 
TNF stimulates an inflammatory response that removes the sources of disturbance and, 
ultimately, restores functionality and homeostasis to the tissue. However, when deregulated, 
inflammation can drive chronic tissue remodelling and repair, which contributes to 
inflammatory diseases, cancer and treatment failure (Mantovani et al., 2008). Accordingly, 
TNF plays a pre-eminent role in the development of chronic inflammatory diseases as well as 
cancer-related inflammation.  
 
In mammals, binding of TNF to its extracellular receptor TNF-R1 triggers either pro-
survival/inflammatory or pro-death signalling pathways in a Ub- and phosphorylation- 
dependent manner (Silke, 2011; Vanlangenakker et al., 2011; Walczak, 2013). TNF can 
regulate tissue homeostasis in at least three different ways: 1) activation of NF-kB and 
MAPK/JNK- transcriptional programmes, 2) induction of caspase-8-dependent apoptosis or 3) 
stimulation of Receptor interacting protein kinase (RIPK)-mediated necroptosis (Declercq et 
al., 2009).  
 
Binding of TNF to TNF-R1 results in the formation of two signalling complexes (Micheau and 
Tschopp, 2003). Upon TNF ligation, a protein complex assembles on the cytoplasmic tail of 
TNFR1. This complex, frequently referred to as complex-I, consists of TNF-R1, the adaptors 
TRADD, TRAF2, the kinase RIPK1 and the E3 Ubiquitin (Ub)-ligases cellular Inhibitor of 
APoptosis (cIAP) cIAP1 and cIAP2 (Silke, 2011; Ting and Bertrand, 2016). Within this 
complex, RIPK1 and other proteins are rapidly conjugated with M1, K11, K48, K63 Ub linkage 
types (Dondelinger et al., 2016; Dynek et al., 2010; Peltzer et al., 2016). cIAP-mediated 
conjugation of Ub to RIPK1 allows recruitment of the kinase complex TAK1/TAB2/TAB3 and 
the E3 ligase Linear Ub chain Assembly Complex (LUBAC, composed of 
HOIL/HOIP/Sharpin). LUBAC-mediated linear ubiquitylation of different components of 
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complex-I (RIPK1, TRADD and TNFR1) subsequently reinforces complex-I and allows 
efficient recruitment and activation of IKK (composed of NEMO/IKKa/IKKb), which in turn 
drives activation of NF-kB (Elliott et al., 2016; Hrdinka et al., 2016; Kupka et al., 2016; 
Schlicher et al., 2016; Silke, 2011; Wagner et al., 2016). While the synthesis of M1- 
and K63-linked poly-Ub chains play key roles in Ub-dependent assembly of complex-
I and the induction of NF-kB target genes that drive inflammation and cell survival 
following TNF stimulation, the role of K11 and K48 poly-Ub remains largely 
uncharacterized.	
 
TNF-induced cell death is mediated by a RIPK1-containing secondary complex that is 
frequently referred to as complex-II or necrosome (Micheau and Tschopp, 2003; Pasparakis 
and Vandenabeele, 2015; Wang et al., 2008). It is thought that the Ub chains conjugated to 
RIPK1 by cIAP1/2 and LUBAC in complex-I constitute one of the decisive factors preventing 
RIPK1 from forming complex-II, and limiting its killing potential (Bertrand et al., 2008; Haas et 
al., 2009; Peltzer et al., 2016). Consistently, genetic deletion of cIAPs completely abrogates 
RIPK1 ubiquitylation, leading to exaggerated complex-II formation and RIPK1-mediated cell 
death in response to TNF (Moulin et al., 2012). The interpretation of the role of RIPK1 
ubiquitylation in suppressing the cytotoxic potential of RIPK1 is complicated by the fact that 
loss of cIAPs not only abrogates RIPK1 ubiquitylation but also interferes with recruitment of 
LUBAC, TAK1, and IKK. Particularly, loss of TAK1 recruitment prevents activation of MK2 
and IKK, which in turn regulate the cytotoxic potential of RIPK1 via direct phosphorylation 
(Dondelinger et al., 2017; Dondelinger et al., 2015; Jaco et al., 2017; Menon et al., 2017). 
Thus, loss of cIAPs not only interferes with activation of NF-kB, but also abrogates MK2- and 
IKK-mediated suppression of RIPK1 (Bettermann et al., 2010; O'Donnell et al., 2007; 
Vandenabeele and Bertrand, 2012).  
 
While it is beyond doubt that cIAPs suppress TNF-induced cell death, how this is achieved 
remains unclear. The main problem in dissecting cIAP-mediated regulation of TNF-induced 
cell death has been the fact that the signaling aspect of Ub (recruitment/activation of TAK1, 
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IKK, MK2 and NF-kB-mediated gene induction) and the direct Ub-dependent anti-apoptotic 
function of cIAPs cannot be separated. We now identified a point mutation in cIAP1 that 
selectively sensitizes cells to TNF-induced cell death, without interfering with TNF-mediated 
activation of NF-kB, and IKK- and MK2-mediated phosphorylation of RIPK1. This mutation 
affects the evolutionary conserved UBiquitin-Associated domain (UBA) of cIAP1. Mice with a 
knock-in mutation in the UBA domain develop normally but are acutely sensitive to TNF-
induced systemic inflammatory response syndrome (SIRS), which is caused by enhanced 
sensitivity to TNF-mediated cell death. Our data are consistent with the notion that the UBA 
domain is required for Ub-mediated regulation of RIPK1 kinase activity. We find that cIAP1 
represses RIPK1 kinase auto-activation via UBA-mediated ubiquitylation of an expanded 
repertoire of Ub-acceptor lysines of RIPK1. In addition, we find that the UBA domain favours 
K48-linked poly-ubiquitylation of RIPK1, which, in combination with poly-monoubiquitylation, 
destabilises active RIPK1 via proteasomal degradation. In the absence of a functional UBA 
domain, fewer K residues are ubiquitylated, and fewer K48-linked chains are present on 
RIPK1. Together, this causes lethal accumulation of active RIPK1 kinase in response to TNF 
in cIAP1UBAmut cells. Our data demonstrate, for the first time, that cIAP-mediated ubiquitylation 
of RIPK1 directly regulates its kinase activity, independently of the recruitment of IKK and 
TAK1 kinase complexes. 
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Results 
 
Non-canonical interaction between cIAP1 and TRAF2 
The BIR1 and RING domains of cIAP1/2 are required for TNF signalling, but little is known 
about the role of the UBA domain. Because UBA domains often regulate protein activity via 
protein-protein interactions (Dikic et al., 2009; Hicke et al., 2005; Yagi et al., 2012), we 
conducted a yeast two-hybrid experiment with the UBA containing C-terminal portion of cIAP1 
(cIAP1U/C/R) to establish a UBA interactome of cIAP1 (Figure 1A and 1B). This identified 
known as well as novel cIAP1 binding proteins (Figure 1B). Surprisingly, out of the 137 clones 
identified, TRAF2 was isolated 107 independent times. While previous work established that 
TRAF2 binds to the BIR1 domain of cIAP1 and cIAP2 (Samuel et al., 2006; Vince et al., 2009; 
Zheng et al., 2010) (Figure 1A), our data suggest that TRAF2 also associates with the C-
terminal portion of cIAP1. 
 
To narrow down the region within the UBA-CARD-RING fragment that mediates TRAF2 
binding, we trimmed the cIAP1 construct from the C terminus, and determined the ability of 
these truncated proteins to interact with TRAF2. The UBA domain readily interacted with 
TRAF2 (Figure 1C and S1A), and point mutations in the conserved MGF motif of the 
hydrophobic patch of the UBA domain (MF>AA), abrogated the binding of cIAP1 to TRAF2. 
Consistent with the notion that cIAP1 interacts with TRAF2 through a bimodal interaction via 
its BIR1 as well as UBA domain, we found that point mutations in either the BIR1 (ER>AA) or 
UBA domain (MF>AA) did not abolish the interaction between cIAP1 and TRAF2 in yeast-
two-hybrid experiments (Figure 1D and 1E, Figure S1B).   
 
To map the region of TRAF2 that bound to the UBA domain we performed further 
experiments with truncated and mutated TRAF2 variants. Surprisingly, the cIAP-interacting 
motif (CIM) in the TRAF-N domain, which is required for TRAF2 to interact with the BIR1 of 
cIAP1 (Vince 2009), was also indispensable for UBA binding. Accordingly, deletion of the 10 
amino acid CIM motif completely abrogated the interaction between TRAF2 and the UBA 
domain of cIAP1 (Figure 1F, S1C). These data indicate that cIAP1 contains two surfaces on 
very distinct spatially separated domains that somehow bind to the same short TRAF2 motif. 
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Since TRAF2 forms trimers (Zheng et al., 2010) we cannot discern whether the UBA and 
BIR1 bind to the very same CIM of one TRAF2 molecule, or to different CIMs of adjacent 
molecules. 
 
The UBA contributes to TRAF2 binding in solution and in cells  
To independently corroborate the interaction, we performed isothermal titration calorimetry 
(ITC) using recombinant cIAP2. cIAP2 was used instead of cIAP1 because structural 
information of TFAF2/cIAP2 is known, and all previous ITC measurements involved TRAF2 
and cIAP2 (Zheng et al., 2010). Of note, cIAP1’s UBA is 87% similar to the one of cIAP2. 
While the interaction between TRAF2 and the BIR1 domain of cIAP2 exhibits a dissociation 
constant of 1.7 µM (Zheng et al., 2010), we found that the BIR1 in conjunction with the UBA 
domain bound to TRAF2 with a significantly higher affinity (0.43 µM) (Figure 2A and 2B). 
Under the same conditions, the isolated UBA domain bound much less strongly to TRAF2, 
displaying a dissociation constant of 0.48 mM (Figure 2C). 
 
To determine the importance of the UBA domain for TRAF2 binding in a cellular context, we 
used Flp-InTM-RexTM-HEK293 (hereafter referred to simply as Flp-In) cells. These cells carry a 
single FRT site, which allows Flp-mediated integration of transgenes into the same 
transcriptionally regulatable genomic locus. Prior to transgene insertion, isogenic parental 
HEK293Flp-In;shcIAP1 cells bearing a doxycycline-inducible mir30-based shRNA against the 
3’UTR of endogenous cIAP1 were generated and reconstituted either with WT cIAP1 or the 
indicated mutants (Figure 2D). Because HEK293Flp-In cells do not express detectable levels of 
cIAP2 (data not shown), this system ensures single copy insertion and equal expression 
levels of untagged cIAP1 proteins without interference from endogenous cIAPs. Expression of 
the doxycycline-inducible cIAP1 shRNA in parental cells reduced cIAP1 to an almost 
undetectable level, and resulted in concomitant activation of the non-canonical NF-κB 
pathway (Figure 2E). Cells reconstituted with either a WT or a UBA mutant version of cIAP1 
exhibited comparable levels of cIAP1, indicating that the UBA mutation did not affect protein 
stability. Moreover, cIAP1MF>AA suppressed activation of the non-canonical NF-κB pathway 
(Figure 2E, middle blot, compare lane 2 with lanes 4 and 7), and underwent SM-induced 
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auto-ubiquitylation and degradation, indicating that cIAP1MF>AA is able to ubiquitylate NIK and 
itself. Using biotinylated SM as affinity reagent to purify cIAP1 and its binding partners from 
cellular extracts, we found that it readily co-purified TRAF2 with WT cIAP1 (Figure 2F). In 
contrast, and consistent with earlier reports (Samuel et al., 2006; Vince et al., 2009; Zheng et 
al., 2010), we found that mutation of the BIR1 (cIAP1ER>AA) almost completely abolished the 
binding of cIAP1 to TRAF2 (Figure 2F, compare lane 2 with 4). Interestingly, mutation of the 
UBA domain, either via alteration of the MGF motif (MF>AA) or substitutions of E401 and 
N428 to RR (EN>RR), which disrupt UBA-mediated protein:protein interactions (Budhidarmo 
and Day, 2014), likewise impaired TRAF2 binding (Figure 2F and 2G). While mutations in the 
BIR1 (ER>AA) and the UBA domains (MF>AA) retained some binding to TRAF2, combined 
mutation in the BIR1 and UBA (ER>AA/MF>AA) completely abrogated the interaction 
between cIAP1 and TRAF2 (Figure 2F). Together, these data corroborate the notion that 
TRAF2 interacts with cIAP1 via its BIR1 and UBA domain. 
 
The UBA domain is dispensable for embryonic development and the regulation of 
canonical as well as non-canonical NF-κB. 
To study the importance of the UBA domain of cIAP1 in vivo, we generated a conditional 
knock-in mouse bearing the MF>AA mutation in the absence of cIAP2 (Figure 3A). Previous 
work indicated that cIAP1 and cIAP2 function redundantly to each other. This is evident as 
cIAP1 and cIAP2 single knock-out (KO) animals are viable and do not exhibit any overt 
phenotypic abnormalities (Conte et al., 2006; Conze et al., 2005; Moulin et al., 2012), 
whereas cIAP1/cIAP2 double knock-out (DKO) animals die at embryonic stage E10.5 due to 
cardiovascular defects (Moulin et al., 2012). Due to the redundant nature of these cIAPs, we 
generated the conditional cIAP1UBAmut mouse from an ES cell clone that previously had been 
targeted at the cIAP2 locus (Moulin et al., 2012). These doubly targetted animals (cIAP2-/-
cIAP1UBAmut) are subsequently referred to as cIAP1UBAmut. cIAP1UBAmut mice were born and 
weaned at the expected Mendelian ratio (Figure 3B), and were indistinguishable from their 
WT counterparts (Figure S2A and S2B). Additionally, these mice had an overtly normal 
immune system, with T and B cells as well as cells of myeloid origin equally represented in 
WT and cIAP1UBAmut mice (Figure S2C). Primary mouse embryonic fibroblasts (MEFs) 
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isolated from WT and cIAP1UBAmut E13.5 embryos exhibited the same cIAP1 protein levels 
(Figure 3C), indicating that the UBA mutation had no impact on the stability of cIAP1. As 
expected, these cells exhibited undetectable levels of cIAP2 mRNA (Figure S2D). To verify 
whether the UBA mutation affected cIAP1’s E3 ligase function, we tested the ability of SM to 
stimulate auto-ubiquitylation and degradation of cIAP1UBAmut. We found that the behaviour of 
cIAP1UBAmut was indistinguishable from its wild-type counterpart (Figure S2E).  
 
To confirm the importance of the UBA domain for the binding to TRAF2, we purified cIAP1 
using biotinylated SM in cIAP2-/-, cIAP1UBAmut, and Traf2-/- mouse embryonic fibroblasts.  
cIAP2-/- cells were chosen as control given the absence of cIAP2 in the cIAP1UBAmut cells. We 
found that significantly less TRAF2 was co-purified with cIAP1 in cIAP1UBAmut cells, while no 
TRAF2 binding was observed in TRAF2-/- cells (Figure 3D), confirming the data obtained with 
reconstituted human cells (Figure 2F-G). Importantly however, while this immunoprecipitation 
setting reveals a weakened association between cIAP1UBAmut and TRAF2, under physiological 
conditions cIAP1 and TRAF2 are perfectly capable of interacting with each another. This is 
evidenced because the UBA mutation of cIAP1 does not phenocopy loss of TRAF2 (Figure 
3E). Accordingly, RIPK1 is readily poly-ubiquitylated in complex-I in cells from cIAP1UBAmut 
animals, while RIPK1 ubiquitylation is lost in Traf2 KO cells (Figure 3E). Moreover, 
cIAP1:TRAF2-mediated regulation of NIK, and suppression of non-canonical NF-kB, is 
normal in cIAP1UBAmut animals (Figure 3F). On the other hand, depletion of cIAP1WT and 
cIAP1UBAmut by SM or depletion of TRAF2 by TWEAK (Vince et al., 2008) activates non-
canonical NF-kB (Figure 3F). As TRAF2 is essential to bring cIAPs to NIK, this data 
demonstrate that cIAP1UBAmut:TRAF2 association is sufficiently strong in vivo to target NIK for 
ubiquitylation and degradation. Additionally, the UBA domain of cIAP1 was entirely 
dispensable for timely TNF-induced phosphorylation and activation of p65, degradation of 
IkB, phosphorylation of MAPKs (Figure 3G and S2F), and the production of cytokines in 
primary MEFs (Figure 3H and 3I), BMDMs (Figure 3J) and keratinocytes (Figure 3K).  Taken 
together, our data demonstrate that cIAP1UBAmut retains E3 ligase activity, and that the UBA 
domain is dispensable for embryonic development or routine tissue homeostasis. Additionally, 
we conclude that the UBA domain of cIAP1 is not required for RIPK1 ubiquitylation in 
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complex-I, suppression of the non-canonical and activation of the canonical NF-kB pathway. 
 
UBA mutant mice develop normally but are acutely sensitive to TNF-induced systemic 
inflammatory response syndrome (SIRS) 
Next we determined the response of cIAP1UBAmut mice to TNF challenge. Injection of TNF 
provokes systemic inflammation that is driven by RIP kinase-dependent cell death (Duprez et 
al., 2011) and resembles clinical systemic response syndrome (SIRS) (Tracey et al., 1986). 
Strikingly, cIAP1UBAmut mice were much more sensitive to TNF-induced SIRS than wild-type 
and cIAP2-/- counterparts. Accordingly, following administration of a dose of murine TNF as 
low as 4 µg/Kg of body weight, cIAP1UBAmut mice exhibited a dramatic drop in body 
temperature and significant increase in morbidity (Figure 4A and 4B). TNF treated cIAP1UBAmut 
mice also had significantly elevated levels of aspartate transaminase (AST), alanine 
transaminase (ALT) and lactate dehydrogenase (LDH) in the plasma indicating liver and 
tissue damage (Figure 4C and 4D). Consistently, livers from cIAP1UBAmut mice had 
considerably higher numbers of TUNEL positive cells than cIAP2-/- or WT littermate control 
mice, (Figure 4E and 4F). Collectively, these data demonstrate that the UBA of cIAP1 is 
required to protect mice from the lethal effects of TNF. 
 
Mutation in the UBA domain switches the TNF response to cell death 
To examine the role of the UBA domain in regulating the cellular response to TNF we used 
primary bone marrow-derived macrophages (BMDMs), mouse dermal fibroblasts (MDFs) and 
embryonic fibroblasts (MEFs). TNF treatment did not induce substantial cell death in either 
wild-type or cIAP2 deficient cells, however it was a potent cell death stimulus in cIAP1UBAmut 
cells (Figure 5A, 5C, 5D, S3A and S3B). This cell death was RIPK1 kinase dependent 
because treatment with the selective RIPK1 inhibitor GSK’963 (Berger et al., 2015) 
suppressed TNF killing. Likewise, primary cIAP1UBAmut BMDMs were exquisitely more 
sensitive to RIPK1-mediated TNF-induced necroptosis than BMDMs from either wild-type 
littermates or single targeted cIAP2-/- animals (Figure 4A). Consistently, increased association 
of RIPK1 with RIPK3 was detected by Proximity Ligation Assay (PLA) (Figure 5B).  Primary 
MDFs and MEFs instead seemed to die by apoptosis since RNAi-mediated depletion of MLKL 
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had no apparent effect on TNF-induced cell death in cIAP1UBAmut MEFs (Figure S3D). 
Consistently, TNF stimulation of cIAP1UBAmut MDFs and MEFs caused elevated levels of 
caspase activity (Figure S3E), which was accompanied with enhanced complex-II formation 
(Figure 5D and 5F), and cleavage and activation of caspase-8 and caspase-3 (Figure S3F). 
Importantly, cIAP1UBAmut MEFs prepared from multiple embryos within the same litter and 
between litters behaved in the same manner (Figure S3A, S3B and S3C). Together, these 
data suggest that the UBA domain allows cIAP1 to inhibit TNF induced death. 
 
The UBA directly regulates RIPK1 ubiquitylation 
Since ubiquitylation of RIPK1, and other components of complex-I, represses RIPK1-
dependent formation of complex-II, we analysed complex-I formation in MDFs and MEFs. As 
previously reported, deficiency of cIAP1 and cIAP2 prevented ubiquitylation of RIPK1 and the 
recruitment of the LUBAC components SHARPIN and HOIL five minutes after TNF 
stimulation (Figure 6A, compare lane 2 to 5) (Haas et al., 2009). We found no evidence for 
defective ubiquitylation of RIPK1 in complex-I in single targeted cIAP2-/-, but cIAP1 deficient 
MEFs had significantly lower molecular weight modified forms of RIPK1, and substantial 
levels of non-modified RIPK1. cIAP1UBAmut cells, however, displayed a more marked and 
reproducible decrease in the extent of high molecular weight RIPK1 ubiquitylation (arrows) in 
complex-I in both MEFs and MDFs (Figure 6A, 6B and S4A), compared to cIAP2-/- and WT 
cells. Importantly, the extent of non-modified RIPK1 in complex-I was indistinguishable 
between WT, cIAP2-/- and cIAP1UBAmut cells (Figure 6A and 6B, see quantifications), 
suggesting that the same amount of RIPK1 undergoes ubiquitin modifications in these three 
genotypes. Because the same amount of RIPK1 is being ubiquitylated in WT, cIAP2-/- and 
cIAP1UBAmut cells, but overall ubiquitylation of RIPK1 seems to be affected in cIAP1UBAmut cells 
compared to WT and cIAP2-/- cells, we conclude that RIPK1 undergoes Ub modifications that 
are distinct from those observed in wild-type, cIAP1-/- or cIAP2-/- cells. Although the UBA 
mutation resulted in reduced levels of ubiquitylated RIPK1 in complex-I, this had no apparent 
effect on the kinetics of the recruitment of other components of the TNF-RSC such as 
SHARPIN and HOIL-1 (Figure 5A and 5B).  
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Next, we addressed whether the weakened association of cIAP1UBAmut with TRAF2 might lead 
to decreased recruitment of cIAP1 to complex-I and generally decreased ubiquitylation 
mediated by cIAP1 (Figure 6A, compare lane 11 to 14 and 6B, compare lane 8 to 11 for 
cIAP1 levels). To this end, we increased the amount of cIAP1UBAmut to the levels of WT cIAP1 
in complex-I using a Doxocycline-inducible reconstitution approach. This allowed us to induce 
the expression of cIAP1UBAmut so that comparable amount of cIAP1UBAmut protein was present 
in complex-I as in WT or cIAP2 KO cells (Figure 6C, compare lane 2 to 5). Even though the 
levels of cIAP1UBAmut in complex-I was comparable to cIAP1-WT, this did not 
‘normalise/correct’ the ubiquitylation pattern of RIPK1, nor did it have an impact on the 
recruitment of unmodified RIPK1 in complex-I (Figure 6C, compare lane 5 to 8). This 
demonstrates that the different smearing pattern of ubiquitylated RIPK1 in the cIAP1UBAmut 
cells is not due to impaired recruitment of cIAP1 to complex-I, and, therefore, are not TRAF2-
binding-dependent but merely UBA dependent.  
 
The UBA is required for efficient K48-ubiquitylation and degradation of RIPK1 in 
complex-I  
To provide a robust analysis of the composition of Ub linkage types on RIPK1 in cIAP2-/- and 
cIAP1UBAmut cells, we employed absolute quantification (AQUA)-based mass spectrometry of 
RIPK1 in complex-I. To this end, we performed two consecutive immunoprecipitiations (IP), 
first of complex-I (FLAG-TNF) and then of RIPK1 (Figure 7A). Following double purification, 
retained ubiquitylated RIPK1 was subject to tryptic digestion, and the eluate was spiked with 
isotope-labelled GlyGly-modified AQUA peptide standards derived from each linkage type, 
allowing AQUA-based absolute quantification of all chain types. Our analysis revealed that 
K48-linked chains on RIPK1 were reproducibly less abundant (13% reduction) in 
cIAP1UBAmut,cIAP2-/- mutant cells compared to cIAP2-/- (Figure 7A). Beside K63-linked Ub 
chains, no other linkage types were reproducibly detected on RIPK1. Calculations from the 
AQUA-based mass spectrometry experiment indicated that the majority of Ub is conjugated in 
the form of mono-Ub moieties (data not shown) rather than chains, and that the actual chains 
on RIPK1 are surprisingly short, even in the control situation. Given that the overall smearing 
pattern is reduced in cIAP1UBAmut cells, this suggests that not only K48-ubiquitylation is 
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affected but also that the occupancy of acceptor lysine (K) residues is altered.  
 
To test the possibility that the occupancy of acceptor K of RIPK1 from cIAP1UBAmut cells differs 
from the one in control cIAP2-/- cells, we analysed ubiquitylated RIPK1 from complex-I using 
Ub chain restriction (UbiCRest) (Hospenthal et al., 2015) (Figure 7B). To this end, we used a 
combination of deubiquitylating enzymes (vOTU/OTULIN) that remove all chain types but 
leave the most proximal Ub attached to RIPK1. vOTU hydrolyses all Ub-linkage types except 
M1-linked chains, which can be cleaved by OTULIN. Incubation with vOTU/OTULIN revealed 
a reduction in the Ub-site occupancy in cIAP1UBAmut compared to cIAP2-/- (Figure 7B, compare 
lane 5 with 10). The reduced Ub occupancy of RIPK1 might help to explain the shift towards 
the lower molecular weights of ubiquitylated RIPK1 in cIAP1UBAmut cells.  
 
Since K48-linked chains as well as poly-mono-ubiquitylation can target proteins for 
degradation (Braten et al., 2016), we tested whether the combined reduction in poly- and 
mono-ubiquitylation of RIPK1 affects the protein stability of RIPK1 in complex-I. Using 
Tandem Ub Binding Entities (TUBE) (Hjerpe et al., 2009), which allow isolation of 
polyubiquitylated proteins, we found that the levels of ubiquitylated RIPK1 dramatically 
accumulated in cIAP1UBAmut cells compared to WT cells over a 6 hours time period following 
TNF treatment (Figure 7C). Importantly, TNF-induced accumulation of ubiquitylated RIPK1 in 
cIAP1UBAmut cells coincided with a significant increase in formation of complex-II and activation 
of caspase-8 (Figure 7C, bottom three panels). This demonstrates that the UBA domain of 
cIAP1 represses lethal accumulation of RIPK1, most likely by facilitating efficient poly-mono 
as well as K48-mediated ubiquitylation and degradation of RIPK1, which would lower the 
number of ‘seeding’ molecules for formation of complex-II (Jaco et al., 2017). Importantly, 
while ubiquitylated RIPK1 accumulated over time in TNF-treated cIAP1UBAmut cells, treatment 
of cIAP1UBAmut cells with proteasome inhibitors (MG132) did not result in a further increase in 
RIPK1 accumulation (Figure 7D), corroborating the notion that the stabilization effect is due to 
the UBA mutation. While treatment with MG132 did not cause a further stabilization of RIPK1 
in cIAP1UBAmut cells, proteasome inhibition in WT cells resulted in a substantial accumulation 
of RIPK1 in the ubiquitylated proteome (Figure S5A), indicating that under normal conditions 
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RIPK1’s stability is regulated, at least in part, in a Ub- and proteasome-dependent fashion. Of 
note, since RIPK1 forms amyloid like structures upon activation, the TUBE-based experiment 
also purifies non-ubiquitylated RIPK1 that is bound to ubiquitylated RIPK1. We also 
addressed whether the UBA domain might shield ubiquitylated RIPK1 from DUBs. However, 
using a broad-spectrum DUB inhibitor (PR619), we found no evidence for a role of the UBA 
domain in protecting ubiquitylated RIPK1 from DUB digestion (Figure S5B and S5C). 
 
UBA-mediated ubiquitylation of RIPK1 represses its kinase activity  
RIPK1 functions as a scaffold molecule for TNF-mediated gene activation, and as a kinase to 
drive apoptosis or necroptosis (Berger et al., 2014; Peltzer et al., 2016). TNF-induced 
activation of IKK and MK2 directly suppresses the kinase activity and cytotoxic potential of 
RIPK1 (Dondelinger et al., 2017; Dondelinger et al., 2015; Jaco et al., 2017; Menon et al., 
2017). In particular, MK2 directly phosphorylates mouse RIPK1 at serine (S) 321 and S336 
(S320 and S335 in human), which in turn suppresses RIPK1 auto-activation at S166 
(Dondelinger et al., 2017; Jaco et al., 2017; Menon et al., 2017). Since cIAP1UBAmut cells are 
sensitised to RIPK1 kinase mediated cell death in response to TNF, we addressed whether 
the UBA mutation affects MK2-mediated suppression of RIPK1 kinase activity. RIPK1 
immuno-precipitation from TNF-treated cIAP2-/- and cIAP1UBAmut cells revealed a strong 
increase in auto-phosphorylation at S166 in cIAP1UBAmut cells, which is entirely consistent with 
the notion that TNF causes auto-activation of RIPK1, and RIPK1 kinase-dependent cell death 
in these cells (Figure 7E). Intriguingly, activation of MK2 and MK2-mediated phosphorylation 
of S321 was entirely normal in cIAP1UBAmut cells, demonstrating that activation of RIPK1 
kinase activity in cIAP1UBAmut cells was MK2-independent. Similarly, timely activation of IKK 
and NF-kB-mediated expression of target genes was as in WT and cIAP2-/- cells (Figure 3G 
to 3J), suggesting that IKK-mediated regulation of RIPK1 is unlikely to be perturbed in 
cIAP1UBAmut cells. In agreement with this view we found that inhibition of IKK with TPCA-1 
further sensitised cIAP1UBAmut cells to TNF killing (Figure 7F).  
 
Annibaldi et al.  2017 
	 15 
Together, out data are consistent with a model whereby cIAP1 regulates RIPK1 kinase 
activity not only by activating downstream kinases, such as IKK and MK2, but also by directly 
repressing RIPK1 kinase activity via Ub-dependent inactivation. The conjugation of Ub to 
RIPK1 might impede its auto-activation and, in addition, mark it for proteasomal degradation, 
thereby limiting accumulation of cytotoxic RIPK1. 
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Discussion 
Although it is clear that TNF signals cell survival and death, the molecular mechanisms that 
can switch between the distinct outcomes remain ill defined. Ub-mediated inactivation of 
RIPK1 has long been postulated to contribute to the regulation of cytokine-induced cell death 
(Ea et al., 2006; Moquin et al., 2013; O'Donnell et al., 2007). However, detailed insights into 
the determinants and the actual molecular and functional consequences of RIPK1 
ubiquitylation have not been demonstrated. Here we show that the UBA domain of cIAP1 
interacts with TRAF2 and is required for proper regulation of RIPK1 kinase activity. In the 
absence of a functional UBA domain, more active RIPK1 kinase accumulates in response to 
TNF, causing RIPK1 kinase-mediated cell death and systemic inflammatory response 
syndrome.  
 
UBA-mediated ubiquitylation of RIPK1 seems to regulate RIPK1 kinase activity through two 
potentially interconnected mechanisms: First, the UBA domain is required for optimal Ub 
occupancy of RIPK1. This is evident as fewer K residues are conjugated to Ub in cells from 
cIAP1UBAmut animals. While this reduction in ubiquitylation of RIPK1 has no effect on its 
scaffolding function, such as activation of TAK1, IKK, MK2, the induction of NF-kB target 
genes and the production of cytokines, reduced RIPK1 ubiquitylation severely compromises 
proper regulation of RIPK1 kinase activity, leading to enhanced RIPK1 auto-phosphorylation 
and formation of complex-II. Second, the UBA domain of cIAP1 also contributes to the 
regulation of cytotoxic potential of RIPK1 by targeting it for proteasomal degradation. In the 
absence of a functional UBA domain, fewer poly-mono and K48-linked chains are conjugated 
to RIPK1 in complex-I.  
 
Although the overall difference in K48-ubiquitylation of RIPK1 is a mere 13%, this causes a 
significant alteration of RIPK1’s stability as active, ubiquitylated RIPK1 accumulates over time 
in cIAP1UBAmut cells. Since K48-linked chains as well as poly-mono-ubiquitylation can target 
proteins for degradation (Braten et al., 2016) it is highly likely that the combined reduction in 
poly- and mono-ubiquitylation of RIPK1 ultimately contributes to the increased protein stability 
of RIPK1 in complex-I from cIAP1UBAmut cells, leading to exacerbated RIPK1 kinase activity in 
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response to TNF. Thus, under normal conditions, the conjugation of Ub to RIPK1 might 
impede its auto-activation and, in addition, mark it for proteasomal degradation, thereby 
limiting accumulation of cytotoxic RIPK1. Clearly, the ability of cIAP1 to suppress the 
cytotoxic potential of RIPK1 not only depends on UBA-mediated regulation of RIPK1. In 
addition to the above-mentioned regulation, cIAP1 represses RIPK1 auto-activation by 
facilitating Ub-mediated recruitment of LUBAC and activation of IKK and MK2. While it is 
currently unclear how LUBAC supresses RIPK1 kinase activity, Ub-mediated recruitment 
and/or activation of IKK and MK2 reportedly regulate RIPK1 kinase activity through inhibitory 
phosphorylation (Dondelinger et al., 2017; Dondelinger et al., 2015; Jaco et al., 2017; Menon 
et al., 2017). Our current data are consistent with a revised model for TNF signalling whereby 
RIPK1’s kinase activity is suppressed through both Ub-mediated phosphorylation of RIPK1 by 
IKK and MK2 as well as by direct Ub-mediated inactivation and degradation of RIPK1. 
Therefore, kinase- and Ub-mediated regulation of RIPK1 serve as survival checkpoints for 
cell fate in inflammation.  
 
The ability of cIAP1 to target RIPK1 for degradation depends on activation of TNFR1. In the 
absence of receptor engagement, cIAP1 does not regulate RIPK1 levels, potentially because 
HSP90 sequesters RIPK1 in its monomeric, kinase inactive state (Lewis et al., 2000). Thus, 
under resting conditions, RIPK1 seems to reside in an inactive configuration that precludes 
cIAP1/TRAF2 binding. Only when it is recruited to TNFR1 does it get into proximity of 
cIAP1/TRAF2. In this respect, cIAP1 may sense the activity status of RIPK1. Recruitment of 
cIAP1 to TNF-RSC reportedly depends on TRAF2. Unexpectedly, we find that the UBA 
domain of cIAP1 contributes to efficient TRAF2 binding. Consistent with the notion that cIAP1 
interacts with TRAF2 through a bimodal interaction via its BIR1 as well as UBA domain, we 
find that point mutations in either the BIR1 or UBA domain weakens the interaction between 
cIAP1 and TRAF2. Although cIAP1UBAmutant proteins bind less well to TRAF2 in co-
immunoprecipitation studies under resting conditions, under in vivo settings this association is 
sufficient to maintain TNF-induced activation of NF-kB or support TRAF2/TRAF3-mediated 
degradation of NIK. Importantly, despite the fact that UBA mutant cIAP1 interacts less 
efficiently with TRAF2 under IP conditions, the reduced ubiquitylation of RIPK1 in complex-I 
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observed in cIAP1UBAmutant cells is not due to impaired cIAP1 recruitment. This is evident as 
elevating the levels of cIAP1UBAmut expression, which causes a corresponding increase in 
cIAP1UBAmut recruitment into complex-I that is comparable to the one of WT or cIAP2-/- cells, 
does not ‘normalise/correct’ the ubiquitylation pattern of RIPK1. Further evidence is provided 
by the fact that the UBA mutation of cIAP1 does not phenocopy loss of TRAF2. Accordingly, 
RIPK1 is readily ubiquitylated in complex-I in cells from cIAP1UBAmut animals. In contrast, 
RIPK1 ubiquitylation in complex-I is completely lost in TRAF2 KO cells. Taken together, our 
data demonstrate that cIAP1UBAmut retains E3 ligase activity, and that the UBA domain is 
dispensable for embryonic development or routine tissue homeostasis. Additionally, we 
conclude that the UBA domain of cIAP1 is not required for (i) K63-ubiquitylation of RIPK1 in 
complex-I, (ii) suppression of the non-canonical and (iii) activation of the canonical NF-kB 
pathway. Consistently, cells lacking a functional UBA do not show any deficit in TNF-induced 
activation of NF-kB, MAPK signalling or the production of pro-inflammatory cytokines. Thus, 
the elevated sensitivity to the cytotoxic potential of TNF cannot be explained by the regulation 
of NF-kB or MK2.  We propose that the UBA mutation provides rare insight into the protein 
architecture of complex-I. We suggest that the UBA contributes to the proper positioning of 
the RING domain of cIAP1 within complex-I so that the Ub-loaded E2 enzyme can optimally 
transfer ubiquitin to RIPK1.  
 
As TNF is a key player in the cytokine network that supports inflammation-associated cancer, 
and cancer-related inflammation (Mantovani et al., 2008) it will be important to gain a better 
understanding of the checkpoints that control life and death decisions in response to TNF. A 
better understanding of such checkpoints could lead to new approaches for the treatment of 
chronic inflammatory diseases that are fueled by aberrant RIPK1-induced cell death, and/or 
reveal novel strategies for anti-cancer immunotherapies that harness RIPK1’s ability to trigger 
immunogenic cell death (Yatim et al., 2015). 
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METHODS 
 
Mice generation 
The cIAP2 and cIAP1 genes are positioned 10 Kb apart on the same chromosome. Hence, 
they recombine as a single genomic locus. The cIAP2FRT/FRTcIAP1minigene mouse was 
generated by electroporating the cIAP1 targeting vector into C57BL6-derived ES cells that 
were previously targeted on the cIAP2 locus (Moulin et al., 2012). For the cIAP1 targeted 
allele the M396A and F398A mutations were introduced into exon 4 and a F3 site-flanked 
PGK-Hygro selection cassette was inserted upstream of the genetically altered exon 4. A 
mini-gene corresponding to exon 4-7 of cIAP1 and a BGH poly-A signal were placed 
upstream of the selection cassette. The cDNA mini-gene is flanked by loxP sites. Mice 
carrying the cIAP2FRT/FRTcIAP1minigene alleles were crossed to transgenic mice expressing the 
FLPo recombinase to generate the cIAP2-/-cIAP1minigene animals. The PGK-Hygro resistance 
cassette on the cIAP1 targeted allele was also deleted by the FLPo-mediated recombination. 
The cIAP2-/-cIAP1minigene mice were subsequently crossed to transgenic mice expressing the 
Cre recombinase to delete the mini-gene and generate the cIAP2-/-cIAP1UBAmut animals. 
cIAP2-/-cIAP1loxP/loxP mice were a gift from John Silke, and were previously described (Moulin 
et al., 2012). 
 
Mice injections monitoring and sampling 
Experiments in mice were performed at the Department of Pharmacology of the Faculty of 
Veterinary Medicine of the Ghent University, Belgium, according to institutional, national and 
European regulations. Animal protocols were approved by the ethics committee of Ghent 
University. mTNF was diluted in endotoxin-free PBS and injected intravenously (i.v.) in a 
volume of 0.2 ml. Rectal body temperature was recorded with a digital thermometer (model 
2001; Comark Electronics). Plasma samples and tissue samples of liver were collected at 
designated times after injection. Blood was obtained by cardiac puncture. 
 
Isolation of primary cells  
Primary Mouse Embryonic Fibroblasts (MEFs) were generated from E13.5 embryos. After 
removing the placenta, yolk sac, head and the dark red organs, embryos were finely minced 
and digested for 20 min in 0.25 % trypsin. Single cell suspension was then obtained by 
pipetting up and down the digested embryos. Mouse Dermal Fibroblasts (MDFs) were 
isolated as described in (Etemadi et al., 2015).  To generate Bone Marrow Derived 
Macrophages (BMDMs), bone marrow cells from tibia and femur of 2 month old mice were 
seeded in non-coated petri dishes and cultured for 6 days in Dulbecco’s modified Eagle 
medium + 10 % fetal bovine serum + 20 % (v/v) L929 mouse fibroblast conditioned medium. 
Keratinocytes were isolated as described in (Lichti et al., 2008). Splenocytes were isolated 
from 2 month old mice. Mouse spleens were mashed through a cell strainer into the petri dish 
using the plunger end of a syringe. Cells were then washed once in cold PBS and treated 
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with 1X Red Blood Cell Lysis Buffer (BioLegend, Cat N 420301) for 5 min on ice. Cells were 
then washed again in PBS and counted.  
 
Splenocytes FACS analysis 
5 x 105 splenocytes were resuspended in 500 μl of cold PBS and stained with DAPI (1/5000) 
for 20 min on ice. Cells were then washed with cold PBS and resuspended in 50 μl Staining 
Buffer. 2 μl of blocking antibody (Anti-Mouse CD16/CD32) were added, and cells were kept 
on ice for 10 min. 50 μl of Staining Buffer containing the desired antibodies were then added 
and cells were kept on ice for 30 min. Cells were washed in cold PBS, resuspended in 1 ml of 
cold PBS and analysed by FACS. 
 
Cell culture, constructs and transfection 
Primary MEFs, MDFs and Flp-InTM-RexTM-HEK293 cells were cultured in Dulbecco’s modified 
Eagle’s Medium (DMEM) supplemented with 10 % Fetal Bovine Serum (FBS), penicillin and 
streptomycin under 10 % CO2. For the generation of the 293 stable cell lines, where 
endogenous cIAP1 was reconstituted with WT and mutant cIAP1, Flp-InTM T-RExTM 
HEK293shcIAP1 cells were created. First Flp-InTMT-RExTM-HEK293 cells (Invitrogen) were 
transduced with lentiviral particles targeting the 3’ UTR of the cIAP1 mRNA. To this end, we 
used pTRIPZ-shcIAP1 (Open Biosystems), which allows Doxocycline-inducible expression of 
a miR30-based shcIAP1 RNA. After puromycin selection, individual clones were tested for 
cIAP1 knockdown efficiency. Such cells were further tested functionally using TNF signalling 
and NIK activation as readouts. Next, the respective cIAP1 constructs were cloned into 
pcDNA5.1/FRT/TO (Invitrogen). The empty pcDNA5.1/FRT/TO-2HA-Strep plasmid was used 
as a control. To generate site-specific single copy insertions, pcDNA5.1FRT/TO-based 
plasmids were co-transfected with pOG44 into Flp-InTMT-RExTM-HEK293shcIAP1 cells. After 
selection with hygromycin, stable cells were selected. Endogenous cIAP1 suppression and 
expression of WT or mutant versions of cIAP1 were simultaneously induced by treating cells 
with 100 ng/ml Doxycycline for at least 48 hours. 
 
Reagents, Constructs and Antibodies 
The GSK’963 RIPK1 kinase inhibitor was provided by GSK. The following antibodies were 
used: α-RIPK1 (BD Biosciences, 610459), α-HOIL (gift from Henning Walczak), α-cIAP1 
(Enzo, ALX-803-335-C100), α-TNFR1 (Abcam, 19139), α-Actin (Santa Cruz Biotechnology, 
sc-1615), α-P-p65 (Cell Signaling, 3033), α-p65 (Cell Signaling, 8242), α-IkBα (Santa Cruz, 
sc-371), α-P-p38 (Cell Signaling, 9215), α-p38 (Cell Signaling, 9212), α-P-JNK (Cell 
Signaling, 9255), α-JNK (Santa Cruz Biotechnology, sc-571), α-P-ERK (Cell Signaling, 9101), 
α-ERK (gift from Chris Marshall) α-caspase-8 (Cell Signaling, 9429), α-FLAG [M2] (SIGMA, 
M8823), α-Ub (Dako, Z0458), α-FLIP (Adipogene, AG-20B-0056), α-FADD (Santa Cruz 
Biotechnology, sc-6036), α-RIPK3 (ProSci, 2283), α-Tubulin (SIGMA, T9026), α-SHARPIN 
(Proteintech, 14626-1-AP), α-TRAF2 (Cell Signaling, 4712), α-CD8-PE-Cy7, GR-1-PE-Cy7, 
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CD11c-FITC, CD4-FITC, CD11b-Cy5, B220-FITC (gift from Henning Walczak), α-CD69-PE 
(eBioscience, 12-0691-82), α-CD3-APC (eBioscience, 47-0032-82), and α-CD16 
(eBioscience, 14-0161-82). 
 
UbiCRest analysis 
The UbiCRest analysis with linkage selective DUBs was performed essentially as described 
in (Hospenthal et al., 2015). Briefly, the release fraction (see complex-I purification) was 
incubated with the following DUBs: 1 μM OTULIN, 0.5 μM vOTU, 1.5 μM USP21. The 
reaction was conducted in the presence of 1 mM DTT for 30 min at 37 °C. Reactions were 
stopped with SDS sample buffer, and the ubiquitylation status analysed by western blotting. 
 
Tube Assay 
Cells were lysed in DISC lysis buffer (20 mM Tris-HCL pH7.5, 150 mM NaCl, 2 mM EDTA, 1 
% Triton X-100, 10 % glycerol) supplemented with protease inhibitors, 1 mM DTT, PR619 (10 
μM) and GST-TUBE (50 μg/ml; 50 μg TUBE/mg protein lysate). Cell lysates were rotated at 
4°C for 20 min then clarified at 4 °C at 14,000 rpm for 10 min. 20 μl GST beads were added 
and immunoprecipitations were performed overnight. Beads were washed 4x in wash buffer 
(50 mM Tris pH 7.5, 150 mM NaCl, 0.1 % Triton X-100, and 5 % glycerol) + PR619 (10 μM), 
and bound proteins eluted by boiling in 50 μ l 1x SDS loading dye. 
 
Complex-I/II Purification 
Cells were seeded in 15 cm dishes and treated as indicated with 3x FLAG-hTNF (5 μg/ml). To 
terminate stimulation, media was removed and plates were washed with 50 ml of ice cold 
PBS. Plates were frozen at -80 °C until all time points were acquired. Plates were thawed on 
ice and cells were lysed in 1 % Triton X-100 lysis buffer (30 mM Tris-HCl pH 7.4, 120 mM 
NaCl, 2 mM EDTA, 2 mM KCl, 10% glycerol and 1 % Triton X-100, supplemented with 
protease inhibitors and PR619 (10 μM). Cell lysates were rotated at 4 °C for 20 mins then 
clarified at 4 °C at 14,000 rpm for 30 mins. Proteins were immunoprecipitated from cleared 
protein lysates with 20 μl of α-FLAG M2 beads (SIGMA) with rotation overnight at 4°C. For 
the 0 hr sample 5 μg/ml of FLAG-TNF were added post-lysis. 4x washes in 1 % Triton X-100 
buffer with PR619 (10 μM) were performed, and samples eluted by boiling in 60 μl 1x SDS 
loading dye. For complex-II purification cells were seeded in 10 cm dishes and treated as 
indicated using media containing 1x FLAG-TNF (100 ng/ml) and zVAD (10 μM). Cells were 
lysed on ice in 1 % Triton X-100 lysis buffer (30 mM Tris-HCL pH 7.4, 120 mM NaCl, 2 mM 
EDTA, 2 mM KCl, 1 % Triton X-100 supplemented with protease inhibitors and 10 μM 
PR619). Cell lysates were rotated at 4 °C for 20 mins then clarified at 4 °C at 14,000 rpm for 
10 mins. 20 μl of protein G sepharose (SIGMA), blocked for 1 hr with lysis buffer containing 1 
% BSA, were bound with FADD antibody (1.5 μg antibody/mg protein lysate) and were 
rotated with cleared protein lysates 4 hrs at 4 °C. 4x washes in lysis buffer were performed, 
and samples eluted by boiling in 80 μl 1x SDS sample buffer. 
Annibaldi et al.  2017 
	 22 
 
Cell death analysis 
2 x 105 cells (MEFs and MDFs) were seeded in six well plates and 24 hrs later they were 
treated as indicated for an additional 24 hrs. Hoechst 33342 (10 μg/ml) and Propidium Iodide 
(PI) (1 μg/ml) were added. After 2 mins 10 to 15 images per well were taken with a 
fluorescent inverted microscope and the ration of dead/live cells were counted manually. 5 x 
104 BMDMs were seeded in 96 well plates and 24 hrs later they were treated as indicated for 
an additional 24 hrs. Hoechst (0.5 μg/ml) and PI (1 μg/ml) were added and the ratio dead/live 
cells was measured using the Celigo imaging system. 
 
Production of recombinant proteins and isothermal titration calorimetry 
Various human cIAP2 and TRAF2 segments were cloned into pSUMO vector respectively to 
produce N-terminally His-SUMO tagged proteins. The constructs were then transformed into 
BL21 (DE3) cells and cultured in LB medium at 37 oC, respectively. Protein expression was 
induced overnight at 20 oC with 0.5 mM IPTG when OD600 reached 0.8. Cells were lysed in 
buffer containing 25 mM Tris-HCl at pH 8.0, 150 mM NaCl, 10 mM imidazole and 5 mM β-
mercaptoethanol. The recombinant proteins were affinity-purified by Ni-Sepharose beads (GE 
Healthcare Life Sciences). The SUMO tag was removed by overnight digestion with 
homemade ULP1 protease at 4 °C. The untagged proteins were further purified by HiTrap Q 
anion exchange and Superdex 200 gel filtration chromatography (GE Healthcare Life 
Sciences). Isothermal titration calorimetry measurements were performed at 16 °C, using a 
MicroCal ITC200 microcalorimeter (MicroCal Inc.).	 For the TRAF2:cIAP2 interactions, the 
calorimetric titrations were performed by injecting 2 μl of cIAP2 protein solution (2–4 mM) into 
a sample cell containing 200 µl 0.20 mM TRAF2 protein in 25 mM Tris-HCl at pH 8.0, 150 mM 
NaCl. A total of 20 injections were performed with a spacing of 150 s and a reference power 
of 6 μcal/s. Binding isotherms were plotted and analysed using Origin Software (MicroCal 
Inc.). 
 
Caspase activity assay (DEVDase) 
2 x 105 cells (MEFs) were plated in 6-well plates and treated as indicated in 2 ml for the 
indicated times. After treatment, media was removed, and 300 μl 1 % DISC lysis buffer (20 
mM Tris-HCL pH 7.5, 150 mM NaCl, 2 mM EDTA, 1 % Triton X-100, 10 % glycerol) was 
added to each well, cells were scraped and lysates were left on ice for 5 min. 50 μl of lysate 
per condition were transferred into a 24 well plate and 450 μl DEVDase assay mix (20 mM 
Ac-DEVD-AMC (Sigma), 1 mM DTT, 50 mM Tris pH 7.5, 150 mM NaCl, 0.1 % Triton X-100, 
and 5 % glycerol) was added to each well (NB: cell lysates were not cleared). Plates were 
wrapped in foil and reactions allowed to proceed by incubation at room temperature for up to 
24 hrs. DEVDase activity was read at 380 nM excitation/460 nM emission. 
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Yeast two- and three-hybrid 
The yeast strain Y2HGold (Clontech) was co-transformed with the respective bait and prey 
plasmids. Positive transformants were selected on minimal SD-Leu-Trp medium 
(Formedium). Three single colonies for each bait and prey co-transformation were patched 
out on fresh SD-Leu-Trp plates and grown for 2 days at 30 ºC. Each patch was resuspended 
in 180 μl of sterile water in a 96-well plate and replica plated onto non-selective (SD-Leu-Trp) 
or selective medium (SD-Leu-Trp-His), containing the indicated concentration of 3-amino-
1,2,4-triazole (3-AT, Formedium). Yeast plates were incubated at 30 ºC for 1 week. UbcH5b 
prey vector was provided by Rachel Klevit. 
 
Protein expression and purification 
BL21 cells were transformed with pGEX6p-1-3XFLAG-TNF plasmid. One colony was picked 
and incubated o/n in 100 ml LB medium with 100 μg/ml ampicillin. Next day 900 ml of LB 
medium without AMP were added, cells were grown for 1 h at 37 °C and then 0.5 mM IPTG 
was added for further 4 h. Bacteria were spun for 15 min at 4000 rpm, the supernatant was 
discarded and the pellet was lysed in 10 ml Triton X-100 lysis buffer (10 mM Tris pH 7.5, 150 
mM NaCl, 10 % glycerol and 1 % Triton X-100 with complete protease inhibitor cocktail). The 
lysate was sonicated and left for 15 min at 4 °C and clarified for 30 min at 140,000 rpm at 4 
°C. Lysate was rotated with glutathione Sepharose beads for 4 hrs at 4 °C and 3x washed 
with IPPG150 buffer (0,1 % Triton X-100, 50 mM Tris pH 7.5, 150 NaCl, 5 % glycerol) were 
performed, followed by a final wash in PreScission cleavage buffer (50 mM Tris pH 7, 150 
mM NaCl, 1 mM EDTA and 1 mM DTT). For PreScission cleavage 500 µl cleavage buffer and 
30 µl PreScission enzyme were added to the beads at 4 °C o/n. The beads were spun, and 
supernatants were collected and passed through Thermo Scientific buffer exchange columns 
to remove bead contamination. Recombinant TNF concentration was determined on 
Coomassie Blue-stained polyacrylamide gel using known amount of BSA as standard, and 
quantitated using Image Lab software. 
 
Proximity ligation assay (PLA) 
PLA was performed according to the manufacturer’s protocol using the Duolink Detection Kit 
(SIGMA). Cells were examined with a confocal microscope (Objective 40x, Zeiss LSM 710). 
 
Ub Chain Composition Mass Spectrometry Analysis 
Ub chains were separated on a NuPAGE 4%–12% gradient gel (Invitrogen) before in-gel 
digestion with trypsin and the addition of Ub-AQUA peptide internal standards according 
to (Kirkpatrick et al., 2006). 10 μl of each sample was directly injected onto an EASY-Spray 
reverse-phase column (C18, 3 μm, 100 Å, 75 μm × 15 cm) using a Dionex UltiMate 3000 
high-pressure liquid chromatography system (Thermo Fisher Scientific) and analysed on a Q-
Exactive mass spectrometer (Thermo Fisher Scientific) using parallel reaction monitoring 
(PRM), similar to (Tsuchiya et al., 2013). Data were analysed further according to (Kirkpatrick 
et al., 2006) 
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FIGURE LEGENDS 
 
Figure 1. The UBA domain of cIAP1 interacts with TRAF2 
(A) Schematic representation of the domain architecture of cIAPs and TRAF2, and the 
interaction between cIAPs and TRAF2. (B) Schematic representation of the putative 
interaction partners of cIAP1, identified by yeast two-hybrid using the C-terminal portion 
(encompassing the UBA/CARD/RING region) of cIAP1 as bait.  (C-F) Yeast two-hybrid 
analysis studying the interaction between the indicated cIAP1 fragments and TRAF2 variants. 
Shown are three single colonies for each cotransformation grown on nonselective (SD-Leu-
Trp) or selective medium (SD-Leu-Trp-His, containing the indicated 3AT concentration).  
 
Figure 2. cIAP2 requires a functional UBA domain to efficiently interact with TRAF2 
(A-C) Binding of the indicated cIAP2 fragments to TRAF2 was measured by Isothermal 
Titration Calorimetry. KD: Binding constant. Note, the data shown in (A) was previously 
published (Zheng et al., 2010) and is shown for comparison reason. (D) Schematic diagram 
of the Flp-InTMT-RExTM-HEK293shcIAP1 cell system in which endogenous cIAP1 was knocked 
down via inducible expression of mir30-based short hairpin RNA targeting cIAP1’s 30 UTR. 
These cells also carry a single FRT site that allows Flp-mediated integration of transgenes 
into the same transcriptionally regulatable genomic locus. Expression of the transgene and 
the mir30-based shcIAP1 are induced following treatment with Doxocycline (Dox). TRE, 
tetracyclin response element; UBC, ubiquitin promoter; FRT, flippase recognition target; Tet 
Op, tetracycline operon; Tet-R, tet repressor protein; rtTA3, reverse Tet transactivator (rtTA3). 
(E) Western blot analysis of Flp-In cells treated for 72 hrs with Dox (100 ng/ml), to allow 
expression of the indicated transgenes, followed by treatment with the SMAC mimetic (SM) 
Compound A (100 nM) for 6 hrs. (F and G) Biotinylated SM was used to purify IAPs from 
lysates of Flp-In cells that were treated with Dox for 72 hrs. TRAF2-binding was then 
assessed by immunoblotting. In parallel, expression levels of cIAP1 and TRAF2 were 
controlled by immunoblotting total cell lysates with the respective antibodies. Representative 
immunoblots are shown of at least three independent experiments. 
 
Figure 3. Mice with a knock-in mutation in the UBA domain develop normally and do 
not exhibit defects in the canonical and non-canonical NF-kB activation 
(A) Gene targeting strategy for the generation of mice with conditional deletion of cIAP2 and 
conditional mutation of the UBA domain of cIAP1. Exon 2 and 3 of cIAP2 were flanked by 
FRT sites. To generate the UBA mutation, M396 and F398 were mutated to A396 and A398, 
respectively.  A targeting vector containing a lox-P flanked-minigene spanning exon 4 to 7 of 
cIAP1 followed by a stop sequence and a hygromycin resistance sequence was used to 
ensure the WT expression of cIAP1 and therefore the conditional expression of the UBA 
mutation. (B) Expected and observed numbers of mice with the respective genotypes. (C) 
Western blot analysis of cIAP1 protein levels of WT and cIAP1UBAmut MEFs obtained from 
three different embryos. (D) Biotinylated SM was used to purify IAPs from lysates of cIAP2-/- 
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and cIAP1UBAmut MEFs. TRAF2-binding was then assessed by immunoblotting. In parallel, 
expression levels of cIAP1 and TRAF2 were controlled by immunoblotting total cell lysates 
with the respective antibodies. (E) Purification of the TNF-receptor signalling complex 
(complex-I) from immortalized MEFs. Cells of the indicated genotypes were treated with 
FLAG-TNF for 0, 5 and 60 mins. Cell lysates were then subjected to FLAG immune-
precipitation followed by Western blot analysis with the indicated antibodies. Representative 
images of at least three independent experiments are shown. (F) Western blot analysis of 
cIAP2-/-  and cIAP1UBAmut MEFs treated with SM (100 nM) and TWEAK for 6 hrs, followed by 
Western blot analysis using the indicated antibodies. (G) Western blot analysis of MEFs with 
the indicated genotypes treated with TNF and harvested at the indicated times points. (H and 
I) The presence of relative mRNA levels (H) and cytokines in the culture media (I) of MEFs 
treated with TNF (10 ng/ml) for the indicated time points were analysed by RT-PCR and 
ELISA, respectively. (J and K) Primary WT and cIAP1UBAmut BMDMs and keratinocytes were 
treated with TNF (10 ng/ml) for 2 and 6 hrs, and mRNA levels of the indicated cytokines were 
measured by RT-PCR. 
 
Figure 4. Mice with a knock-in mutation in the UBA domain develop normally but are 
acutely sensitive to TNF-induced systemic inflammatory response syndrome (SIRS) 
(A and B) Body temperature and survival of WT (D, n=11; E, n=12) and corresponding 
littermate cIAP1UBAmut (D, n=8) or cIAP2-/- (E, n=11) mice injected with 4 µg of mTNF. Data are 
representative of two independent experiments. Survival curves were compared using log-
rank Mantel-Cox test (* p<0.05, *** p<0.001). (C and D) Plasma samples of WT and 
cIAP1UBAmut (F) or cIAP2-/- (G) mice were collected at the indicated time points following 
challenge with mTNF (4 µg, i.v.) and analysed for activities of LDH, AST and ALT. n=4 per 
time point and genotype. Data are presented as mean ± SD, ** p<0.01, statistics were 
performed using two-way ANOVA. (E and F) TUNEL staining and quantification of liver 
sections of WT and cIAP1UBAmut mice used in C and D. Of note, data shown in A and B were 
obtained from two sets of animals, while the data shown in C-F were obtained from a third set 
of animals.  
 
Figure 5. Mutation in the UBA domain switches the TNF response to cell death 
(A, C, E) Primary BMDMs (A), MDFs (C) and MEFs (E) of the indicated genotypes were 
treated as shown (TNF 100 ng/ml, GSK’963 100 nM, SM 100 nM, for BMDMs TNF 1 ng/ml) 
for 24 hrs followed by quantification of Propidium Iodide (PI) positive cells. Data are 
presented as mean ± SD, n>3, * p<0.05 *** p<0.001, statistics were performed using two-way 
ANOVA. (B) PLA of primary BMDMs from cIAP2-/- and cIAP1UBAmut animals using RIPK1 and 
RIPK3 antibodies.  Cells were stimulated with 1 ng/ml TNF for the indicated time points. The 
graph to the side indicates the quantification of RIPK1/RIPK3 PLA speckles. (D and F) 
Primary MDFs (D) and MEFs (F) of the indicated genotypes were treated for 4 hrs as 
indicated (TNF 100 ng/ml, z-VAD-FMK 10 µM), followed by FADD immuno-precipitation and 
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Western blot analysis for the indicated proteins. Images are representative of at least three 
independent experiments.  
 
Figure 6. The UBA directly regulates RIPK1 ubiquitylation 
(A and B) Purification of the TNF-R1 signalling complex (complex-I) from primary MEFs (A) 
and MDFs (B). Cells of the indicated genotypes were treated with FLAG-TNF for 0, 5 and 60 
mins. Cell lysates were then subjected to FLAG immune-precipitation followed by Western 
blot analysis with the indicated antibodies. Representative images of at least three 
independent experiments are shown. (C) Purification of the TNF-R1 signalling complex 
(complex-I) from immortalized cIAP2-/- and cIAP1UBAmut MEFs reconstituted either with empty 
vector (control) or a doxycycline inducible construct encoding cIAP1UBAmut.  
 
Figure 7. UBA-mediated ubiquitylation of RIPK1 represses its kinase activity and 
facilitates RIPK1 degradation in response to TNF 
(A) Absolute quantification (AQUA)-based mass spectrometry of RIPK1 in complex-I. The 
scheme indicates the double purification strategy to isolate RIPK1 in complex-I. Pie charts 
indicating the ubiquitin linkage types detected on RIPK1 in complex-I from cIAP2-/- and 
cIAP1UBAmut MEFs in two independent replicates. (B) UbiCRest analysis of ubiquitylated 
RIPK1 in complex-I. Complex-I was purified from cIAP2-/- and cIAP1UBAmut MEFs using FLAG-
TNF as affinity reagent. Immuno-complexes were then subjected to UbiCRest analysis using 
the indicated DUBs followed by Western blot analysis for RIPK1. (C) cIAP2-/- and cIAP1UBAmut 
MEFs were treated with TNF (100 ng/ml) for the indicated time points. Lysates were then split 
in two and subjected either to FADD immune-precipitation (complex-II) or TUBE pull-down 
(ubiquitylated proteome), followed by Western blot analysis with the indicated antibodies. 
Representative images of at least three independent experiments are shown. (D) cIAP1UBAmut 
MEFs were incubated for 1 hr with MG132 (20 µM) or left untreated and then subjected to 
TNF stimulation for the indicated time points. TUBE pull-down was then carried out on cell 
lysates followed by Western blot analysis with the indicated antibodies. (E) 
Immunoprecipitation of RIPK1 in cIAP2-/- and cIAP1UBAmut MEFs followed by immunoblotting 
analysis with the indicated antibodies. (F) cIAP2-/- and cIAP1UBAmut MDFs were treated as 
indicated for 24 hrs (TNF 100 ng/ml, TPCA-1 1 µM) followed by quantification of Propidium 
Iodide (PI) positive cells. 
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Supplementary Information 
 
Supplementary Figure S1. Interaction of the UBA domain of cIAP1 with TRAF2, Related 
to Figure 1 
(A-C) Yeast two-hybrid negative control. The indicated bait constructs were co-transformed 
with the empty prey vector pACT2 to rule out autonomous growth.  
 
Supplementary Figure S2. The UBA domain of cIAP1 is dispensable for normal 
development and NF-KB-induced gene expression, Related to Figure 3 
(A) Aging curves for WT and cIAP1UBAmut mice. (B) Representative images of 2 months old 
WT and cIAP1UBAmut mice. (C) FACS analysis of hematopoietic cells isolated from the spleen 
of WT and cIAP1UBAmut mice. Cells were analysed using antibodies for the indicated cell 
surface markers. (D) RT-PCR analysis of cIAP2 mRNA levels in WT, cIAP2-/- and cIAP1UBAmut 
MEFs. (E) TUBE affinity purification of the ubiquitylated proteome from WT and cIAP1UBAmut 
MEFs treated with the indicated agents. TUBE pull-down was followed by Western blot 
analysis with the indicated antibodies. (F) Western blot analysis of MDFs with the indicated 
genotypes treated with TNF and harvested at the indicated times points. 
 
Supplementary Figure S3. Mutation in the UBA domain switches the TNF response to 
cell death, Related to Figure 5 
(A-C) Primary MEFs of the indicated genotypes were treated with TNF (100 ng/ml) for 24 hrs 
followed by quantification of PI positive cells. (D) WT and cIAP1UBAmut primary MEFs were 
transfected either with siRNA control or with siRNAs targeting Mlkl. After 72 hrs following 
transfection, cells were treated as indicated, and cell death was measured by scoring PI 
positive cells. (E) DVDase analysis of primary MEFs of the indicated genotypes subjected to 
indicated treatments for 8 hrs (z-VAD-FMK 10 µM), data are presented as mean ± SD, n=3, * 
p<0.05, statistics were performed using two-way ANOVA. (F) Western blot analysis of 
activated caspase-8 and caspase-3 of the indicated MEFs treated with the indicated agents 
for 12 hrs. 
 
Supplementary Figure S4. The UBA domain facilitates cIAP1-mediated degradation of 
RIPK1, Related to Figure 6 
(A) Purification of the TNF-receptor signalling complex (complex-I) from primary MEFs of the 
indicated genotypes. Cells of the indicated genotypes were treated with FLAG-TNF for 0, 5 
and 60 mins. Cell lysates were then subjected to FLAG immune-precipitation followed by 
Western blot analysis with the indicated antibodies. Representative images of at least three 
independent experiments are shown.  
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Supplementary Figure S5. cIAP1 targets RIPK1 to proteasomal degradation, Related to 
Figure 7 
(A) WT MEFs, either pre-incubated with MG132 for 1 hour or left untreated, were treated with 
TNF (100 ng/Ml) for the indicated time points. Cell lysates were subjected to TUBE pull-down 
followed by USP2 digestion. Western blot analysis for the indicated proteins was then carried 
out. (B) WT MEFs were treated with the pan-DUB inhibitor PR619 for 2 hrs. Cell lysates were 
subjected to TUBE pulldown followed by Western blot analysis using an Ubiquitin specific 
antibody. (C) WT MEFs were treated with TNF in the presence of the pan-DUB inhibitor 
PR619 for 2 hrs, and complex-I was purified using FLAG-TNF as affinity reagent. The 
presence of the indicated proteins was analysed using the indicated antibodies. 
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